Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Mar 28

PMID 38540143

Authors

Nikolett Nagy

Bernadett Boi

Gabor Papp

Edit Fiak

Eszter Gaspar-Kiss

Bianka Perge

Nikolett Farmasi

Tunde Tarr

Affiliations

Soon will be listed here.

Abstract

In systemic lupus erythematosus (SLE), cardiovascular complications are among the leading causes of death. Cardiovascular risk in SLE is even higher in the presence of antiphospholipid antibodies or secondary antiphospholipid syndrome (APS). The aim of this retrospective, single-center study was to investigate the occurrence of antiphospholipid antibodies and non-thrombotic cardiac manifestations in 369 SLE patients. We also assessed the clinical and laboratory characteristics of the patients to reveal the risk factors for cardiac manifestations. Patients were divided into two groups based on the presence of antiphospholipid antibodies (APA); 258 (69.9%) patients were APA positive, and 111 (30.1%) patients were APA negative. Mitral and tricuspid insufficiency, aortic stenosis and pulmonary arterial hypertension were more common in APA-positive patients. Anticardiolipin IgG showed the strongest correlation with any non-thrombotic cardiac manifestations. Based on our results, the adjusted global antiphospholipid syndrome score (aGAPSS) above 8.5 is predictive of valvulopathies and ischemic heart disease, while aGAPSS above 9.5 is predictive of cardiomyopathies. The presence of antiphospholipid antibodies may affect the development of cardiac manifestations in SLE. Periodic cardiological and echocardiographic screening of patients without cardiac complaints, as well as regular monitoring of antiphospholipid antibodies, have great importance during the treatment of SLE patients.

References

Amigo M, Garcia-Torres R . Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis. Curr Rheumatol Rep. 2000; 2(3):262-70. DOI: 10.1007/s11926-000-0089-4. View

Tarr T, Lakos G, Bhattoa H, Soltesz P, Shoenfeld Y, Szegedi G . Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clin Rev Allergy Immunol. 2007; 32(2):131-7. DOI: 10.1007/s12016-007-0009-8. View

Laurent C, Ricard L, Nguyen Y, Boffa J, Rondeau E, Gerotziafas G . Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study. RMD Open. 2023; 9(1). PMC: 10069563. DOI: 10.1136/rmdopen-2022-002534. View

Turiel M, Sarzi-Puttini P, Peretti R, Bonizzato S, Muzzupappa S, Atzeni F . Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol. 2005; 96(4):574-9. DOI: 10.1016/j.amjcard.2005.04.022. View

Hussain K, Gauto-Mariotti E, Cattoni H, Arif A, Richardson C, Manadan A . A Meta-analysis and Systematic Review of Valvular Heart Disease in Systemic Lupus Erythematosus and Its Association With Antiphospholipid Antibodies. J Clin Rheumatol. 2020; 27(8):e525-e532. DOI: 10.1097/RHU.0000000000001464. View

Zuily S, Regnault V, Selton-Suty C, Eschwege V, Bruntz J, Bode-Dotto E . Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011; 124(2):215-24. DOI: 10.1161/CIRCULATIONAHA.111.028522. View

Jouhikainen T, Stephansson E . Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus. 1994; 3(3):167-72. DOI: 10.1177/096120339400300307. View

Espinosa G, Cervera R . Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol. 2015; 11(10):586-96. DOI: 10.1038/nrrheum.2015.88. View

Nagy N, Papp G, Gaspar-Kiss E, Dioszegi A, Tarr T . Changes in Clinical Manifestations and Course of Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome over Three Decades. Biomedicines. 2023; 11(4). PMC: 10136176. DOI: 10.3390/biomedicines11041218. View

10.

Calcaterra I, Tufano A, Lupoli R, Iannuzzo G, Emmi G, Di Minno M . Cardiovascular disease and antiphospholipid syndrome: how to predict and how to treat?. Pol Arch Intern Med. 2020; 131(2):161-170. DOI: 10.20452/pamw.15415. View

11.

Kolitz T, Shiber S, Sharabi I, Winder A, Zandman-Goddard G . Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form. Front Immunol. 2019; 10:941. PMC: 6522847. DOI: 10.3389/fimmu.2019.00941. View

12.

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta M, Bertolaccini M . The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxford). 2014; 54(1):134-8. DOI: 10.1093/rheumatology/keu307. View

13.

Cervera R, Font J, Pare C, Azqueta M, Perez-Villa F, Lopez-Soto A . Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis. 1992; 51(2):156-9. PMC: 1005649. DOI: 10.1136/ard.51.2.156. View

14.

Tselios K, Urowitz M . Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Curr Rheumatol Rev. 2017; 13(3):206-218. DOI: 10.2174/1573397113666170704102444. View

15.

Del Barrio-Longarela S, Martinez-Taboada V, Blanco-Olavarri P, Merino A, Riancho-Zarrabeitia L, Comins-Boo A . Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study. Clin Rev Allergy Immunol. 2021; 63(2):297-310. PMC: 9464174. DOI: 10.1007/s12016-021-08915-9. View

16.

Ward N, Linares-Koloffon C, Posligua A, Gandrabur L, Kim W, Sperber K . Cardiac Manifestations of Systemic Lupus Erythematous: An Overview of the Incidence, Risk Factors, Diagnostic Criteria, Pathophysiology and Treatment Options. Cardiol Rev. 2020; 30(1):38-43. DOI: 10.1097/CRD.0000000000000358. View

17.

Petri M . Antiphospholipid syndrome. Transl Res. 2020; 225:70-81. PMC: 7487027. DOI: 10.1016/j.trsl.2020.04.006. View

18.

Roldan C, Gelgand E, Qualls C, Sibbitt Jr W . Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol. 2005; 95(12):1441-7. DOI: 10.1016/j.amjcard.2005.02.010. View

19.

Xourgia E, Tektonidou M . Management of Non-criteria Manifestations in Antiphospholipid Syndrome. Curr Rheumatol Rep. 2020; 22(9):51. DOI: 10.1007/s11926-020-00935-2. View

20.

Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View